Non-commercial clinical trial of CAR-T therapy with Medical Research Agency funding
Medical Research Agency has signed a contract for the implementation of the project called "Polish Chimeric Antigen Receptor T-cell Network", thanks to which patients in Poland will have access to the most modern treatment methods.
CAR-T cell therapy is the most advanced and personalized technology used in the treatment of hematooncology, which involves creating a drug for each patient based on their own lymphocytes. The use of the immune system to fight cancer consists in taking T lymphocytes from the patient, which are then genetically modified in the laboratory. This gene encodes the production by T lymphocyte of a receptor recognising specific antigens of cancer cells. CAR-T cell therapy can achieve complete remission in approx. 90 percent. patients with acute lymphoblastic leukemia,
The project will be implemented by a consortium consisting of:
- Medical University of Warsaw - leader of the consortium
- Pomeranian Medical University in Szczecin,
- Medical University of Lodz.
- National Institute of Oncology im. Maria Skłodowska Curie
- Hospital, University Clinical Center of Warsaw Medical
- University, Institute of Hematology and Transfusiology,
- Transfiguration Clinical Hospital of Maria Skłodowska Curie Medical University,
- Warsaw Medical University. The University Hospital No. 1 in Poznan, the University Hospital No. 1 in Poznan,
- University Hospital No. 2 in Poznan. Dr. Antoni Jurasz in Bydgoszcz.
We have allocated PLN 100 million for the project.